Special Issue "Genetics of Ovarian Cancer"

A special issue of Cancers (ISSN 2072-6694). This special issue belongs to the section "Cancer Pathophysiology".

Deadline for manuscript submissions: closed (20 October 2023) | Viewed by 646

Special Issue Editors

1. Faculty of Life Sciences & Medicine, School of Cancer & Pharmaceutical Sciences, King's College London, London SE1 9RT, UK
2. Medway NHS Foundation Trust, Windmill Road, Gillingham ME7 5NY, Kent, UK
3. Kent Medway Medical School, University of Kent, Canterbury CT2 7LX, Kent, UK
4. AELIA Organization, 9(th)Km Thessaloniki-Thermi, 57001 Thessaloniki, Greece
Interests: prostate cancer; renal cancer; ovarian cancer; homologous recombination of DNA; PARP inhibitors; cervical cancer; carcinoma of unknown primary; colorectal cancer; cancer and autoimmune diseases; biomarkers
Special Issues, Collections and Topics in MDPI journals
1. High Dimensional Neurology Group, UCL Queen's Square Institute of Neurology, London WC1N 3BG, UK
2. 10Department of Oncology, Guy's and St Thomas' Hospital, London SE1 9RT, UK
3. School of Cancer & Pharmaceutical Sciences, King's College London, Strand, London WC2R 2LS, UK
Interests: novel MRI techniques; ovarian cancer;prostate cancer

Special Issue Information

Dear Colleagues,

Epithelial ovarian cancers (EOC), characterised by recurrent, persistent disease and the rapid acquisition of chemotherapy resistance, remain one of the most lethal gynaecological malignancies. DNA damage is one of the hallmarks of cancer. Among EOC, the high-grade serous subtype harbours a defect in at least one DNA damage response (DDR) pathway. Defective DDR results from a variety of lesions affecting homologous recombination (HR) and nonhomologous end joining (NHEJ) for double strand breaks, base excision repair (BER), and nucleotide excision repair (NER) for single strand breaks and mismatch repair (MMR).

We are pleased to invite you to submit your manuscripts and help the community to understand that DDR pathways are essential in order to optimize the therapeutic choices, as well as highlight the importance of designing biomarker-driven clinical trials. Poly(ADP-ribose) polymerase (PARP) inhibitors are a well-established treatment of EOC. Moreover, combinations of PARP inhibitors with drugs that inhibit HR may sensitise EOC with a primary or secondary HR proficiency to PARP inhibitors and potentially expand their use beyond HR-deficient ovarian cancers. Regarding this, PARP inhibitors may be combined separately with anti-angiogenics and immune checkpoint inhibitors as well as with phosphoinositide 3-kinase (PI3K), protein kinase B (AKT), mammalian target of rapamycin (mTOR), WEE1, mitogen-activated protein kinase (MEK), and cyclin-dependent kinase (CDK) 4/6 inhibitors, or even with standard chemotherapy.

Through this Special Issue, we aim to shed light on the mechanisms of DDR, the potential for genomic analysis of ovarian cancer, and therapeutics of PARP inhibitors, along with predictive biomarkers.

This Special Issue welcomes manuscripts that include, though it is not limited to, the following topics:

  • EOC risk assessment in the era of next-generation sequencing;
  • Predictive and prognostic biomarkers in EOC;
  • DNA damage response;
  • PARP inhibitors in EOC;
  • PARP inhibitors in combination with other therapies;
  • Immunotherapy in EOC;
  • Chemoresistance;
  • Regression;
  • Invasion.

We look forward to receiving your contributions.

Dr. Stergios Boussios
Dr. Sola Adeleke
Guest Editors

Manuscript Submission Information

Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All submissions that pass pre-check are peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.

Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Cancers is an international peer-reviewed open access semimonthly journal published by MDPI.

Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2900 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.


  • epithelial ovarian cancer
  • genomics
  • epigenetics
  • translational research
  • biomarkers
  • DNA damage response
  • PARP inhibitors

Published Papers (1 paper)

Order results
Result details
Select all
Export citation of selected articles as:


19 pages, 4299 KiB  
Comprehensive Analysis of DNA Methyltransferases Expression in Primary and Relapsed Ovarian Carcinoma
Cancers 2023, 15(20), 4950; https://doi.org/10.3390/cancers15204950 - 11 Oct 2023
Viewed by 451
Background: Despite recent advances in epithelial ovarian carcinoma (EOC) treatment, its recurrence and mortality rates have not improved significantly. DNA hypermethylation has generally been associated with an ominous prognosis and chemotherapy resistance, but the role of DNA methyltransferases (DNMTs) in EOC remains to [...] Read more.
Background: Despite recent advances in epithelial ovarian carcinoma (EOC) treatment, its recurrence and mortality rates have not improved significantly. DNA hypermethylation has generally been associated with an ominous prognosis and chemotherapy resistance, but the role of DNA methyltransferases (DNMTs) in EOC remains to be investigated. Methods: In the current study, we systematically retrieved gene expression data from patients with EOC and studied the immunohistochemical expression of DNMTs in 108 primary and 26 relapsed tumors. Results: Our results showed that the DNMT1, DNMT3A, DNMT3B and DNMT3L RNA levels were higher and the DNMT2 level was lower in tumors compared to non-neoplastic tissue, and DNMT3A and DNMT2 expression decreased from Stage-II to Stage-IV carcinomas. The proteomic data also suggested that the DNMT1 and DNMT3A levels were increased in the tumors. Similarly, the DNMT1, DNMT3A and DNMT3L protein levels were overexpressed and DNMT2 expression was reduced in high-grade carcinomas compared to non-neoplastic tissue and low-grade tumors. Moreover, DNMT1 and DNMT3L were increased in relapsed tumors compared to their primaries. The DNMT3A, DNMT1 and DNMT3B mRNA levels were correlated with overall survival. Conclusions: Our study demonstrates that DNMT1 and DNMT3L are upregulated in primary high-grade EOC and further increase in relapses, whereas DNMT3A is upregulated only in the earlier stages of cancer progression. DNMT2 downregulation highlights the presumed tumor-suppressor activity of this gene in ovarian carcinoma. Full article
(This article belongs to the Special Issue Genetics of Ovarian Cancer)
Show Figures

Figure 1

Back to TopTop